It is reported that most DFSP have the translocation t(17; 22) (q22; q13), resulting in the COL1A1-PDGFβ fusion gene, which provides a biological basis for treatment with tyrosine kinase inhibitors, such as imatinib [52]. Here, PDGFB is linked to dermatofibrosarcoma protuberans.